Study of a Novel Antipsychotic ITI-007 in Schizophrenia
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether ITI-007 is effective in reducing symptoms
associated with schizophrenia in patients who are having an acute worsening of their
psychosis. Patients will be randomly assigned to receive one of two doses of ITI-007,
placebo, or a positive control. The primary goal will be to assess the effects of ITI-007 on
psychosis. The safety of ITI-007 will also be assessed.